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Objectives This study investigated the effect of catheter-based renal sympathetic denervation (RD) on central hemodynam-
ics in patients with resistant hypertension.
Background High central blood pressure (BP) increases cardiovascular events and mortality independently of peripheral BP.
The effect of RD on central BP is unclear.
Methods A total of 110 patients underwent bilateral RD. Radial artery applanation tonometry and pulse wave analysis
were used to derive central aortic pressure and hemodynamic indices at baseline and 1, 3, and 6 months after
ablation. Ten patients with resistant hypertension not undergoing RD served as controls.
Results RD significantly reduced mean central aortic BP from 167/92 mm Hg to 149/88 mm Hg, 147/85 mm Hg, and
141/85 mm Hg at 1, 3, and 6 months (p  0.001), respectively. Aortic pulse pressure decreased from 76.2 
23.3 mm Hg to 61.5  17.5 mm Hg, 62.7  18.1 mm Hg, and 54.5  15.7 mm Hg 1, 3, and 6 months after
RD (p  0.001), respectively. Six months after RD aortic augmentation and augmentation index were signifi-
cantly reduced by 11 mm Hg (p  0.001) and 5.3% (p  0.001), respectively. Carotid to femoral pulse wave
velocity showed a significant reduction from 11.6  3.2 m/s to 9.6  3.1 m/s at 6 months (p  0.001). Consis-
tently, ejection duration and aortic systolic pressure load were significantly diminished, indicating improvement
of cardiac work load by RD. No significant changes were obtained in control patients.
Conclusions Besides the known effect of RD on brachial blood pressure, the study showed for the first time that this novel
approach significantly improves arterial stiffness and central hemodynamics, which might have important prog-
nostic implications in patients with resistant hypertension at high cardiovascular risk. (J Am Coll Cardiol 2012;
60:1956–65) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.959p
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rArterial hypertension affects more than one-quarter of the
adult population worldwide (1). Despite broad availability
of effective pharmaceutical agents, a substantial proportion
of hypertensive patients do not reach blood pressure (BP)
targets (2,3). Therapy refractory hypertension is a major risk
factor for myocardial infarction, stroke and mortality (2,4).
Renal sympathetic nerves are crucial for the development
and maintenance of arterial hypertension by regulating renin
release, tubular sodium reabsorption, and renal blood flow
(5). To reduce renal sympathetic afferent and efferent activity,
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accepted August 8, 2012.a novel percutaneous, catheter-based approach directly target-
ing the renal sympathetic nerves by applying endovascular
radiofrequency energy in the renal arteries has been developed
(6). In a multicenter, randomized trial this minimally invasive
rocedure effectively reduced systolic blood pressure (SBP) and
iastolic blood pressure (DBP) measured over the brachial
rtery in patients with resistant hypertension (7).
Conventional brachial cuff BP measurements are widely
ssumed to accurately reflect pressures in the central circu-
ation. This assumption is supported by consistent observa-
ions that brachial BP values are powerful predictors of
ardiovascular events, morbidity, and mortality (4). How-
ver, central aortic pressure parameters and left ventricular
oad are determined not only by cardiac output and periph-
ral vascular resistance but also by the stiffness of conduit
rteries and the timing and magnitude of pressure wave
eflections (8,9). Increasing evidence indicates that aortic
ulse wave velocity (PWV), which is inversely related to
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composite measure that depends on the site and degree of
reflection, are independent predictors of cardiovascular
structural damage and clinical outcomes (10–15). Further-
more, central BP may be differentially affected by antihy-
pertensive drugs, despite a similar reduction of brachial BP,
which was suggested to explain different drug effects on
clinical endpoints (16). The impact of renal catheter abla-
tion on PWV and AIx is unclear. Therefore, we evaluated
whether this new therapeutic approach, besides lowering
brachial BP, has a positive effect on central hemodynamic in
patients with resistant hypertension.
Methods
The study was approved by the local ethic committees in
accordance with the Declaration of Helsinki. Patients were
treated between October 2009 and September 2011 with
subsequent follow-up for 6 months. All patients provided
written informed consent.
Study subjects. Eligible patients were older than 18 years
and had an office BP of 160 mm Hg (150 mm Hg for
type 2 diabetics) or more, despite treatment with at least 3
antihypertensive drugs, with no changes in medication for a
minimum of 3 months prior to enrollment. To exclude
white coat hypertension, 24-h BP recordings and home BP
protocols were consulted in addition to office BP measure-
ments at the hospital before enrollment. Patients with
secondary causes of hypertension were excluded. Further
exclusion criteria were renal insufficiency with an estimated
glomerular filtration rate 45 ml/min/1.73 m2 (using the
simplified Modification of Diet in Renal Disease formula)
(17), renal artery anatomy ineligible for treatment (main
renal arteries 4 mm in diameter or 20 mm in length,
emodynamically or anatomically significant renal artery
tenosis or abnormality in either renal artery, a history of
rior renal artery intervention including balloon angioplasty
r stenting, multiple main renal arteries in either kidney),
regnancy, type 1 diabetes mellitus, hemodynamically sig-
ificant valvular heart disease, unstable angina, or myocar-
ial infarction or stroke within the last 6 months before
nrollment (7,18,19). One hundred and ten patients under-
ent renal denervation and 10 patients were in the control
roup. In all patients the same inclusion/exclusion criteria were
pplied as part or extension of the randomized controlled
ymplicity HTN-2 protocol (NCT00888433) (7).
emodynamic. Prior to BP measurements drug adherence
as ensured via interview and by reviewing home BP
rotocols. Blood pressure and heart rate were recorded after
0 min of supine rest using an automatic oscillometric
onitor (Omron HEM-705, Omron Healthcare, Vernon
ills, Illinois) on the brachial artery. Blood pressure was
easured on the same side throughout the study. Averages of
riplicate measurements with 1-min intervals were used for
nalysis. Mean blood pressure (MBP) was calculated from SBP
nd DBP as: MBP  DBP  0.4(SBP – DBP) (20).For assessments of arterial
tiffness, a commercially available
pplanation tonometer (Sphyg-
oCor, AtCor Medical Ltd,
ydney, Australia) was used in
onnection with analysis soft-
are (version 8.0, SphygmoCor
ardiovascular Management
uite), as previously described
11). In short, peripheral radial
rtery waveforms were recorded
sing a high-fidelity microma-
ometer (Millar Instruments,
ouston, Texas). Recorded pres-
ure waveforms were calibrated
o the statistic mean of 3 succes-
ive brachial cuff BP measure-
ents recorded on the same arm immediately before apply-
ng the tonometer (see previous). After 30 to 45 s of
ecording duration, a validated mathematical transfer func-
ion (21,22) was applied to generate the central aortic
aveform. The inflection point representing the merging
oint of the incident and the reflected pressure wave was
alculated and used to quantify the augmentation pressure.
he augmentation index (AIx) was defined as the augmen-
ation pressure expressed as percentage of the aortic pulse
ressure. To minimize the influence of heart rate on AIx,
he AIx corrected for a heart rate of 75 beats/min was
erived (23). Only recordings of sufficient quality with
evice-generated operator index values above 80 (maximum
f 100) were used for analysis.
Carotid to femoral pulse wave velocity (PWVcf) was
easured with the same device by sequentially recording
lectrocardiogram-gated arterial waveforms at the femoral
nd carotid arteries, as previously described (24). PWVcf
was calculated by dividing the pulse wave travel distance by
the pressure wave transit time. The pulse wave travel
distance was assessed by subtracting the distance from the
suprasternal notch to the carotid artery recording site from
the suprasternal notch to the femoral artery recording site,
resulting in best correspondence with invasively measured
aortic PWV (20,25). To minimize intraindividual variabil-
ity, pulse wave velocity was measured 2 times during every
visit and the average of both recordings was used for
statistical analysis. Reference values for PWV corrected for
MBP according to age categories were calculated on the
basis of the regression equations recently suggested (20).
he clinical assistant trained and specialized to perform the
ecordings of central waveforms was blinded to the treat-
ent allocation of the patients.
enal denervation procedure. Renal angiograms were
performed via femoral access to confirm anatomic eligibility.
In the same session, the treatment catheter (Symplicity and
Flex by Ardian Inc., Palo Alto, California) was introduced
into each renal artery using a guiding catheter. Up to 6
Abbreviations
and Acronyms
AIx  augmentation index
BP  blood pressure
DBP  diastolic blood
pressure
MBP  mean blood
pressure
PWV  pulse wave velocity
PWVcf  carotid to femoral
pulse wave velocity
RD  renal sympathetic
denervation
SBP  systolic blood
pressureablations at 8 W for 2 min each were performed in both
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main renal artery bifurcation to the ostium proximally and
were spaced longitudinally and rotationally under fluoro-
scopic guidance. Catheter tip impedance and temperature
were constantly monitored, and radiofrequency energy de-
livery was regulated according to a predetermined algo-
rithm. Visceral pain at the time of energy delivery was
managed with intravenous analgetics and sedatives. Heparin
was given to achieve an activated clotting time during the
procedure of more than 250s.
Statistical analysis
Data are presented as mean  SD. Differences in the mean
values were compared using a 2-tailed t test for continuous
variables and Fisher-Yates testing for nominal variables.
Changes of all parameters with multiple measurements
including p value for statistical trend were analyzed from
baseline to 1, 3, and 6 months by 2-factor analysis of
variance for repeated measurements. The Scheffé correction
algorithm was used to compute post hoc comparisons of
significant values. A comparison between linear trends in
the treatment group for patients with complete data of all
follow-ups and the control group was performed using the
group square linear trend interaction test. A p value 0.05
was considered statistically significant. All statistical analy-
ses were performed with SPSS statistical software (version
12.0, SPSS Inc., Chicago, Illinois).
Results
One hundred and twenty patients were included in the
study; 110 underwent renal sympathetic denervation (RD),
10 patients served as control. Most patients in the treatment
group were male (70%). The mean age was 63.6 9.9 years.
On average, patients were taking 4.8 antihypertensive drugs.
All patients were maintained on baseline antihypertensive
medication during the study period. The patient demo-
graphic and clinical characteristics did not differ between
the RD and control groups (Table 1).
At baseline, overall mean sitting office SBP in the
treatment group was 181.0 24.7 mm Hg and mean sitting
office DBP was 91.4  12.8 mm Hg with a heart rate of
63.4  11.9 beats/min. Ablation of the renal arteries was
performed without any complications in all patients. Figure 1
shows representative averaged radial artery waveforms and
the resulting derived central aortic waveforms from an
individual patient at baseline and 1 month after renal
denervation. There are clear differences in the morphology
of both the radial and central aortic waveforms. Renal
denervation resulted in a reduction of the systolic peak
pressures, a narrower peripheral and central waveform, and
an attenuation of the late systolic peak in the central aortic
waveform. Consistently, mean brachial systolic and diastolic
pressure, and derived central aortic systolic and diastolic
pressure were already significantly reduced 1 month after
the procedure, and further declined throughout the6 months follow-up (n  59 at 3 months, n  55 at 6
months) (Fig. 2, Table 2). Renal denervation also signifi-
cantly decreased peripheral and central aortic pulse pressures
(Fig. 3, Table 2). There was no significant change in control
patients (n  10 throughout 6 months) (Figs. 2 and 3,
Table 2).
Central aortic systolic pressure wave augmentation was
markedly attenuated after the procedure but not in the control
group (Fig. 4, Table 2). Renal denervation also significantly
decreased Alx and AIx corrected for a heart rate of 75
beats/min during follow-up (Fig. 4, Table 2). Furthermore,
both the ejection duration corrected for the cycle length and
the SBP load assessed by the systolic pressure-time integral
were diminished by the intervention, indicating a reduction of
cardiac systolic work load, while these parameters remained
unchanged in control patients (Table 2).
To obtain the impact of the efficacy of lowering office BP
by RD on central aortic pressures, we separately evaluated
patients with office SBP reduction above and below the
median of 18 mm Hg at 1 month. Expectedly, in those
patients with greater BP decrease improvement of all central
hemodynamic parameters was more pronounced (Table 3).
Twenty-two patients achieved a resting SBP of140 mm Hg at
6 months follow-up and were newly controlled. In these
patients central aortic systolic (121.9  8.9 mm Hg),
diastolic (76.7  8.6 mm Hg), and pulse pressure (44.0 
8.0 mm Hg) were also within the age-corrected normal range
6 months after RD. Notably, the degree of BP reduction
following RD appeared to correlate with the severity of initial
hypertension. In patients with BP values above the median
office SBP of 177 mm Hg, the reduction after RD was
significantly larger than in those with lower initial SBP values
Baseline CharacteristicsTable 1 Baseline Characteristics
RD Control p Value
Group size (n) 110 10
Age, yrs 63.6 9.9 65.2 7.7 0.489
Male 77 (70%) 8 (80%) 0.324
BMI, kg/m2 29.4 4.5 29.8 3.6 0.748
Coronary artery disease 22 (20%) 3 (30%) 0.927
Atrial fibrillation 16 (14.5%) 1 (10%) 0.973
Stroke 17 (15.5%) 1 (10%) 0.956
Type 2 diabetes 39 (35.5%) 4 (40%) 0.782
Hypercholesterolemia 66 (60%) 7 (70%) 0.403
Smoking 27 (24.5%) 2 (20%) 0.625
Number of antihypertensive drugs 4.8 2.1 5.6 1.9 0.189
Patients receiving (drug classes)
ACE inhibitors/ARBs 100 (91%) 10 (100%) 0.937
Direct renin inhibitors 43 (39%) 4 (40%) 0.396
Beta-blockers 95 (86%) 9 (90%) 0.838
Calcium-channel blockers 76 (70%) 7 (70%) 0.653
Diuretics 90 (82%) 9 (90%) 0.416
Sympatholytics 41 (37%) 4 (40%) 0.584
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
index; DBP  diastolic blood pressure; RD  renal denervation; SBP  systolic blood pressure.(peripheral SBP 24.7  20.9 mm Hg after 1 month vs.
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m Hg vs. 5.9  10.7 mm Hg, p  0.004).
To assess arterial stiffness we measured PWVcf, which is
onsidered the gold standard to determine aortic PWV
oninvasively (10,20). Renal denervation significantly re-
uced PWVcf at 1, 3, and 6 months by 0.97  4.3 m/s
(p 0.053),1.87 3.8 m/s (p 0.002), and2.0 4.0
m/s (p  0.001), respectively (Fig. 5, Table 2). The
intraindividual variation of PWVcf remained constant
hroughout the follow-up with average standard error values
f PWVcf recordings being 0.89  0.63 m/s at baseline,
0.87  0.56 m/s at 1 month, 0.88  0.61 m/s at 3 months,
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Figure 1 Effect of RD on Peripheral
and Central Aortic Waveforms
Examples of peripheral (A) and corresponding derived central aortic (B) wave-
forms at baseline (solid line) and 1 month after RD (broken line). In both pan-
els the dicrotic notch (incision) caused by the closure of the aortic valve is
visible, representing the division between systole and diastole (vertical lines),
the leftward shift demonstrating a reduction of the ejection duration 1 month
after renal denervation (RD) compared with baseline. The aortic augmentation
pressure (AP) from the reflected wave was calculated as the difference
between central peak systolic pressure and the pressure at the inflection point
representing the onset of the reflected wave from the peripheral vascular bed
(arrows). Following RD peripheral and aortic pressure waveforms show a
marked reduction of the systolic (maximum) and diastolic (minimum) pressure,
pulse pressure (distance between minimum and maximum), and AP (arrows).
BP  blood pressure.nd 0.88  0.69 m/s at 6 months. Reference values for tWVcf remain controversial (20). The ESC/ESH guide-
ines proposed a fixed cutoff PWVcf value of 9.6 m/s (12 m/s
ith directly measured distance) (26). Improvement of
WVcf by RD in those patients with a baseline PWVcf
9.6 m/s (n  46) was more pronounced compared to the
total RD group with a reduction of 2.4  2.7 m/s (p 
0.001), 2.5  4.5 m/s (p  0.001), and 2.9  4.1 m/s
(p  0.001) at 1, 3, and 6 month follow-up, respectively
Fig. 5). Because age modifies PWVcf (20,27), we addition-
ally evaluated age-corrected values. In patients with baseline
PWVcf exceeding the double standard deviation of normal
values of their age category (20) (n  37), PWVcf decreased
y 2.9  3.1 m/s (p  0.002), 3.6  4.3 m/s (p 
.002), and4.0 3.6 m/s (p 0.004) 1, 3, and 6 months
fter the procedure, respectively (Fig. 5).
Given that PWV at any age is linearly related to BP (20),
e aimed to estimate whether RD might have any effect on
WVcf beyond BP reduction. Therefore, we analyzed the
ifference between the predicted PWV corrected for the MBP
ccording to age categories on the basis of the regression
quations recently derived from a large reference population
20). At baseline age- and MBP-corrected predicted PWV
as identical to the measured PWVcf values of our popu-
lation (PWVcf – PWVpredicted 0.01  4.75 m/s,
pNS). However, 1, 3, and 6 months after renal denervation
actually measured PWVcf was significantly lower than the
redicted parameters (PWVcf – PWVpredicted: 1 month
1.04 2.25 m/s, p 0.038; 3 months1.68 2.57 m/s,
 0.001; 6 months 1.44  2.44 m/s, p  0.005),
uggesting a possible additional BP-unrelated effect of the
ntervention over time. In addition, to assess the changes of
WVcf independent of BP changes, we evaluated the ratios
f the PWVcf to the change in MBP (MBP), as
reviously reported (28,29). After RD the PWVcf/MBP
ratio increased in the total treatment group (7.5  15.9 vs.
9.3  19.5, p  NS) and in patients with baseline PWVcf
exceeding the double standard deviation of normal values
(14.9  17.5 vs. 26.9  34.3, p  0.001) from 1 month to
months, respectively.
iscussion
esides the known effect of renal denervation on brachial
P (6,7), our study showed for the first time that this novel
pproach significantly improves central hemodynamics. In-
reasingly it is being acknowledged that central aortic BP,
hich is the pressure exerted on the heart and brain, may be
ifferent from the pressure that is measured at the arm, as
he reflected wave is added to a different part of the
aveform (30). Notably, clinical studies have indicated that
entral BP may have predictive value independent of tradi-
ional risk factors and particularly independent of the
orresponding peripheral (i.e., brachial BP) (10–15,31).
mong markers of central hemodynamic arterial stiffness,
ortic pulse pressure, augmentation pressure, and augmen-
ation index have proven to be important parameters for the
1960 Brandt et al. JACC Vol. 60, No. 19, 2012
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which all were positively affected by RD in our patients with
resistant hypertension.
Blood pressure reduction, per se, is the major determinant
of the benefit of antihypertensive treatment. This has been
shown in several placebo-controlled trials, trials that com-
pared more intensive versus less intensive BP-lowering
strategies, and trials comparing different active regimens
(26,32). However, despite a similar peripheral BP decrease
central hemodynamics may be differentially affected by
various classes of BP-lowering drugs depending on their
mode of action (16,33,34). Experimental and clinical data
have shown beneficial effects on central aortic BP, augmen-
tation pressure, and PWV for angiotensin-converting en-
zyme inhibitors (35), angiotensin-1 receptor blockers
(35,36), calcium antagonists of the dihydropyridine type,
and alpha-adrenergic blockers (35,37). Notably, for beta-
blockers an adverse effect on central hemodynamics was
obtained during short-term administration (35), and the
reduction of central aortic pressure and augmentation dur-
ing long-term therapy was markedly smaller than for other
antihypertensive classes (16,33,34,37), which was attributed
to the reduction of heart rate by beta-blockers (37,38). Due
to the nature of resistant hypertension patients in our study
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Figure 2 Effect of RD on Peripheral and Central BP
Peripheral brachial systolic (A) and diastolic blood pressure (BP) (B), and derived
after renal denervation (RD) versus control patients (mean  SEM).were treated with a combination of the most commonantihypertensive drug classes. The fact that arterial stiffness,
aortic pulse pressure, augmentation pressure, and augmen-
tation index were positively affected by RD in addition to
effects of this extensive medication supports the notion of a
synergistic action of RD and antihypertensive drugs on
central hemodynamics.
While the most pronounced effect on central hemody-
namics was obtained after 1 month, there was an additional
continuous effect of RD both on BP and central hemody-
namics throughout the 6-month follow-up. Renal denerva-
tion is likely to decrease BP mainly by diminishing periph-
eral vascular resistance. However, as indicated previously
several parameters besides arterial stiffness such as heart
rate, ejection duration, and stroke volume affect central
hemodynamics, making the definition of RD-related mech-
anisms more complex. Slower heart rate generally results in
prolongation of systolic ejection time, a delay of the peak of
the outgoing pressure wave, and thereby an increased
likelihood that pressure wave reflections will augment the
outgoing wave during systole, with ejection time being the
strongest independent correlate for augmentation index in
some reports (39). In previous studies RD moderately
decreased heart rate by 3.8 to 4.0 beats/min at 3
months, which was nonsignificant in some and statistically
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centrasignificant in other reports (18,40). In the present study RD
Hemodynamic and Pulse Wave Analysis Parameters in RD and Control Patients at Baseline, 1, 3, and 6 MonthsTable 2 Hemodynamic and Pulse Wave Analysis Parameters in RD and Control Patients at Baseline, 1, 3, and 6 Months
RD (n  110) Control (n  10)
Baseline 1 Month 3 Months 6 Months
p Value
for Trend
(n  55) Baseline 1 Month 3 Months 6 Months
p Value
for Trend
(n  10)
p Value for RD
Versus Control
at 6 Months
Basic hemodynamic parameters
Resting SBP, mm Hg 181.0 24.7 161.1 22.8 159.1 22.1 152.1 20.0 0.001 183.9 21.6 181.3 18.5 190.6 16.9 193.9 15.4 0.491 0.001
Resting DBP, mm Hg 91.4 12.8 87.0 14.0 84.0 13.1 83.7 13.5 0.0026 95.3 11.5 97.1 18.9 104.6 15.6 101.5 17.9 0.251 0.001
Peripheral PP, mm Hg 89.3 21.5 73.9 17.6 73.9 20.0 67.7 15.8 0.001 88.8 25.0 84.2 15.2 83.2 14.9 92.4 16.8 0.308 0.001
Heart rate at rest, beats/min 63.4 11.9 60.4 9.4 59.9 9.5 59.4 10.4 0.0001 58.2 8.1 57.2 5.2 56.7 7.5 60.1 7.0 0.160 0.840
Central hemodynamic parameters
Central SBP, mm Hg 167.2 26.4 148.9 23.8 147.0 24.0 140.7 20.5 0.001 170.0 31.2 169.5 20.0 180.5 17.5 182.3 19.2 0.501 0.001
Central DBP, mm Hg 92.5 13.3 88.1 14.6 85.3 13.2 85.3 13.6 0.001 96.9 11.6 94.3 15.2 95.1 18.8 97.0 15.8 0.633 0.016
Central PP, mm Hg 76.2 23.3 61.5 17.5 62.7 18.1 54.5 15.7 0.001 78.6 26.9 75.7 22.3 85.4 23.6 84.3 24.7 0.715 0.001
Augmentation, mm Hg* 26.0 12.7 20.0 9.5 18.8 11.2 15.5 7.9 0.001 30.6 12.7 30.3 12.0 33.5 11.8 34.6 12.9 0.284 0.001
Augmentation index, % 32.7 9.0 30.4 9.2 27.9 11.1 27.4 9.7 0.001 37.7 4.2 38.9 5.3 38.5 4.3 37.3 5.7 0.382 0.006
Augmentation index @ 75 beats/min, %† 27.0 8.2 23.9 9.2 21.0 10.1 20.3 8.7 0.001 29.2 3.7 29.9 5.7 28.5 4.3 29.4 5.5 0.626 0.002
Ejection duration, ms 332.9 30.1 329.9 26.2 331.6 29.8 330.4 31.8 0.092 329.3 32.0 334.5 34.4 330.5 30.8 334.9 32.5 0.589 0.681
Ejection duration, % CL‡ 34.6 4.8 33.0 4.1 32.9 3.5 32.5 4.5 0.002 31.6 4.2 31.3 4.3 29.7 30.8 31.1 2.6 0.545 0.330
Pressure-time integral systolic, mmHg · s§ 2,982.7 605.1 2,621.4 605.7 2,580.8 505.2 2,483.0 544.1 0.001 2,879.6 354.8 2,788.5 557.4 2,763.5 315.8 2,911.9 255.2 0.815 0.038
PWVcf, m/s 11.58 3.2 10.61 2.8 9.71 2.6 9.58 3.1 0.001 11.88 4.3 12.32 2.0 11.36 2.3 12.58 3.1 0.256 0.006
Laboratory tests
Serum creatinine, mg/dl 1.02 0.67 0.98 0.21 1.06 0.38 0.93 0.32 0.213 0.97 0.25 1.02 0.28 0.93 0.34 0.96 0.38 0.256 0.836
GFR, ml/min/1.73 m2 81.6 24.2 84.4 31.4 88.1 34.5 86.3 27.2 0.786 84.5 21.5 88.3 23.1 90.4 21.2 87.3 22.1 0.812 0.414
Values are mean  SD. *Augmentation (P) is the difference between maximal pressure and incident pressure at the first peak. †Augmentation index is proportion of the central pressure wave height attributable augmentation (P) (AIx  (P/PP)  100) corrected for
a heart rate of 75 beats/min. ‡Ejection duration was measured from start of waveform to closure of the aortic valve (see incision in Fig. 1) corrected for the cycle length (CL). §Systolic pressure-time integral is integration of the area under the central pulse pressure (PP)
curve during ejection duration.
DBP  diastolic blood pressure; GFR  glomerular filtration rate; PWVcf  carotid to femoral pulse wave velocity; RD  renal denervation; SBP  systolic blood pressure.
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Effect of Renal Denervation on Arterial Stiffness November 6, 2012:1956–65reduced heart rate to a similar extent (i.e., 3.5 and 4.0
beats/min at 3 and 6 months, respectively. Notably, unlike
instances in which heart rate inversely correlates to ejection
time such as pacing, drug interventions, and exercise
(22,23,39,41,42), RD did not significantly prolong ejection
duration and diminished heart rate corrected ejection time, which
possibly might account for the substantial improvement of central
hemodynamics by RD despite lowering heart rate.
Given that for resistant hypertension per definition no
reasonable further pharmaceutical options are available, the
effect of RD on central hemodynamics at present may not be
compared with other treatment strategies. Nevertheless we
aimed to assess whether RD might exert any additional
effect on central hemodynamics beyond reduction of office
BP in our patients with resistant hypertension. Therefore,
we evaluated the difference between the predicted PWV
corrected for age and MBP as recently suggested (20), and
the measured values for every individual patient at baseline
and after RD. At baseline predicted and real PWV values
were identical: 1) validating the proposed equations in our
patient cohort; and 2) supporting accuracy of the measure-
ments. Notably, after RD actual PWV measures were lower
than the predicted age- and MBP-corrected values; while
this intraindividual decrease on top of BP reduction was
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Figure 3 Effect of RD on Pulse Pressure
Peripheral brachial (A) and central aortic pulse pressure (B) at baseline and 1, 3,
and 6 months after renal denervation (RD) versus control patients (mean  SEM).small, differences still reached statistical significance. Inaddition, we obtained an increase of the PWVcf/MBP
atio after RD particularly in patients with high baseline
WVcf (28,29). Moreover, in patients with a reduction of
office SBP below the median (Table 3), although there was
minimal decrease in central pressure, the reduction in
PWVcf was comparable to that seen in the group with
pronounced office and central pressure response after RD.
These data further support the notion that RD might exert
BP-independent effects on arterial stiffness, and might
indicate dissociation between reduction in arterial stiffness
and wave reflections in systole.
Cardiac afterload and thereby cardiac systolic work load
increase directly with a reduction in elastic distensibility and
indirectly with a faster backward propagation of pulse wave
reflections from the peripheral vascular bed (43,44). In
patients with hypertension and heart failure with a preserved
ejection fraction vascular stiffness and elevated systolic
afterload have been implicated to play an important role in
the pathophysiology of diastolic dysfunction (45–47). In the
present study RD significantly diminished cardiac systolic
work load as evident by shorter ejection duration and
reduced SBP load after the procedure. Notably, similar to a
decrease in PWVcf, reductions in these parameters related to
A 
B  
R D 
C ontrol 
p=0.001 
p=0.003 
p<0.001 
p=0.287 p=0.003 p<0.001 p<0.001 
p<0.001 
p=0.056 
p<0.001 
p=0.410 p=0.047 p=0.024 p=0.002 
R D 
C ontrol 
Baseline 1 Month 3 Months 6 Months 
Baseline 1 Month 3 Months 6 Months 
A
ug
m
en
ta
tio
n 
pr
es
su
re
 (m
m
 H
g)
 
A
ug
m
en
ta
tio
n 
in
de
x 
@
 75
 (%
) 
Figure 4 Effect of RD on Augmentation Pressure
Central aortic augmentation pressure (A) and augmentation index corrected for
a heart rate of 75 beats/min (B) at baseline, and 1, 3, and 6 months after
renal denervation (RD) versus control patients (mean  SEM).
a unde
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November 6, 2012:1956–65 Effect of Renal Denervation on Arterial Stiffnesscardiac stress were also apparent in the group of patients
with only minimal decrease of central pressures (Table 3).
Whether this effect might translate into a clinical improve-
ment of patients with heart failure with a preserved ejection
fraction remains to be determined.
Study limitations. Our study has some potential limita-
tions, including the lack of directly measured central hemo-
dynamics. For obvious practical reasons central BP indices
were derived from radial artery tonometry measurements.
Hemodynamic and Pulse Wave Analysis Parameters in Patients WiAbove or Below the Median of 18 mm Hg at 1 Month After Renal DTable 3 Hemodynam c nd Pulse Wave Analysi Par m t rs inAbove or Below the Median of 18 mm Hg at 1 Month
Parameter
SBP Reductio
Change Versus Baselin
Peripheral SBP, mm Hg 4.2 7.8
Peripheral DBP, mm Hg 2.4 9.5
Peripheral PP, mm Hg 0.3 13.7
Heart rate, beats/min 4.4 6.4
Central SBP, mm Hg 0.9 9.0
Central DBP, mm Hg 2.3 9.6
Central PP, mm Hg 0.3 14.4
Augmentation, mm Hg* 0.6 6.2
Augmentation index, % 0.5 8.1
Augmentation index @ 75 beats/min, %† 2.3 6.7
Ejection duration, % CL‡ 1.7 3.5
Pressure-time integral, systolic, mmHg · s§ 159.3 352.7
PWVcf, m/s 1.4 2.6
Values are mean  SD. *Augmentation (P) is the difference between maximal pressure and inc
attributable augmentation (P) (AIx  (P/PP)  100) corrected for a heart rate of 75 beats/min
Fig. 1) corrected for the cycle length (CL). §Systolic pressure-time integral is integration of the are
Abbreviations as in Table 2.
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Figure 5 Effect of RD on PWVcf
Change of carotid to femoral pulse wave velocity (PWVcf) in the total renal
denervation (RD) group, patients with PWVcf 9.6 m/s at baseline, and
patients with PWVcf exceeding the double standard deviation of normal values
of their age category 1, 3, and 6 months after RD. Values are presented as
mean  SEM and p values versus baseline.The values for central aortic systolic and pulse pressures
depend on the validity and applicability of the generalized
transfer function used to generate the central aortic wave-
forms. Reassuringly, the correspondence between calculated
and directly recorded central aortic systolic and pulse pres-
sures has been found to be within 1 mm Hg (21,48). The
transfer function used to derive the central aortic pressures
is founded on the observation that pressure wave transmis-
sion in the upper limb is remarkably consistent under
different conditions (16). This includes the effects of aging,
disease, drug therapy, and variation in heart rate, thereby
allowing the generalized transfer function to be used to
convert the radial to an aortic pressure wave (22,48,49).
Moreover, we chose to express PWVcf values using the
subtraction distance and intersecting tangent algorithm,
which were shown to very accurately reflect invasive PWV
measures (20–22,25,50). Given the lack of other therapeutic
options for resistant arterial hypertension, we may not
compare effects of RD with other treatment strategies. The
control group is considerably smaller than the treatment
group. Thus on the basis of harmonic means, the compar-
isons between treatment and control are equivalent to 2
groups of 18 subjects each, and the power for comparison of
means is equivalent to two groups of 19. Because half of the
treatment group has data at all the follow-up observations
there is a resultant potential for bias if data might not be
missing at random. The cohort in our study does not allow
analysis of clinical outcome. Future results of this trial with
longer follow-up and a larger cohort of treated patients will
therefore be of interest.
Conclusions
Renal denervation offers a novel and safe catheter-based
fice SBP Reductionvationnts With Office SBP Reduction
Renal Denervation
mm Hg SBP Reduction >18 mm Hg
p Value Change Versus Baseline p Value
0.015 33.4 16.7 0.001
0.354 10.6 10.5 0.001
0.360 21.7 13.8 0.001
0.002 2.8 8.3 0.021
0.598 29.4 19.8 0.001
0.449 10.8 11.4 0.001
0.602 21.0 15.0 0.001
0.446 9.1 8.2 0.001
0.425 3.6 5.6 0.005
0.228 4.5 6.4 0.001
0.030 2.9 3.1 0.001
0.044 617.5 692.7 0.001
0.013 1.8 2.9 0.009
ressure at the first peak. †Augmentation index is proportion of the central pressure wave height
tion duration was measured from start of waveform to closure of the aortic valve (see incision in
r the central pulse pressure (PP) curve during ejection duration.th OfenerPatie
After
n <18
e
ident p
. ‡Ejecapproach for selective reduction of renal sympathetic drive.
1964 Brandt et al. JACC Vol. 60, No. 19, 2012
Effect of Renal Denervation on Arterial Stiffness November 6, 2012:1956–65We demonstrated for the first time that selective denerva-
tion of the renal sympathetic nerves in addition to lowering
peripheral BP significantly improves central hemodynamics
in patients with resistant hypertension. Extrapolating from
results of the CAFE (Conduit Artery Function Evaluation)
trial (16), the effect on central hemodynamics documented
in our study suggests a prognostic benefit of RD in patients
with refractory hypertension, which should be evaluated in
further trials.
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